Literature DB >> 15161795

Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up.

Jennifer M Barker1, Stephanie H Goehrig, Katherine Barriga, Michelle Hoffman, Robert Slover, George S Eisenbarth, Jill M Norris, Georgeanna J Klingensmith, Marian Rewers.   

Abstract

OBJECTIVE: The objective of this study was to determine whether earlier diagnosis of diabetes in prospectively followed autoantibody-positive children lowered onset morbidity and improved the clinical course after diagnosis. RESEARCH DESIGN AND METHODS: The Diabetes Autoimmunity Study in the Young (DAISY) follows genetically at-risk children for the development of diabetes. Increased genetic risk is identified by family history of type 1 diabetes or expression of diabetes-associated HLA genotypes. Of the 2,140 prospectively followed children, 112 have developed islet autoantibodies and 30 have progressed to diabetes. Diabetes onset characteristics and early clinical course of these 30 children followed to diabetes were compared with those of 101 age- and sex-matched children concurrently diagnosed with diabetes in the community.
RESULTS: Pre-diabetic children followed to diabetes were less often hospitalized than the community cases (3.3 vs. 44%; P < 0.0001). They had a lower mean HbA(1c) at onset (7.2 vs. 10.9%; P < 0.0001) and 1 month after diagnosis (6.9 vs. 8.6%; P < 0.0001) but not after 6 months of diabetes. The mean insulin dose was lower in the DAISY group at 1 (0.30 vs. 0.51 U. kg(-1). day(-1); P = 0.003), 6 (0.37 vs. 0.58; P = 0.001), and 12 months (0.57 vs. 0.72; P = 0.03). There was no difference in growth parameters between the two groups. Comparisons limited to children with a family history of type 1 diabetes in both groups showed a similar pattern.
CONCLUSIONS: Childhood type 1 diabetes diagnosed through a screening and follow-up program has a less severe onset and a milder clinical course in the first year after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161795     DOI: 10.2337/diacare.27.6.1399

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  54 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

3.  Alternate Ways to Quantify Antibodies.

Authors:  Kimber M Simmons; Aaron W Michels
Journal:  Diabetes Technol Ther       Date:  2015-11-06       Impact factor: 6.118

4.  Comparison of Metabolic Outcomes in Children Diagnosed with Type 1 Diabetes Through Research Screening (Diabetes Autoimmunity Study in the Young [DAISY]) Versus in the Community.

Authors:  Christine L Chan; Iman Taki; Fran Dong; Michelle Hoffman; Jill M Norris; Georgeanna Klingensmith; Marian J Rewers; Andrea K Steck
Journal:  Diabetes Technol Ther       Date:  2015-06-03       Impact factor: 6.118

Review 5.  Newborn screening: new developments, new dilemmas.

Authors:  N J Kerruish; S P Robertson
Journal:  J Med Ethics       Date:  2005-07       Impact factor: 2.903

6.  Standards of medical care in diabetes--2009.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

7.  The next big idea.

Authors:  Marian Rewers
Journal:  Diabetes Technol Ther       Date:  2013-06       Impact factor: 6.118

8.  Standards of medical care in diabetes--2010.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

Review 9.  The environment and the origins of islet autoimmunity and Type 1 diabetes.

Authors:  S Eringsmark Regnéll; A Lernmark
Journal:  Diabet Med       Date:  2013-02       Impact factor: 4.359

10.  Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset.

Authors:  Taylor M Triolo; H Peter Chase; Jennifer M Barker
Journal:  Diabetes Care       Date:  2009-05       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.